Educational directory entry
Donanemab
Direct answer (B2B summary)
Donanemab (donanemab): neutral, non-prescriptive summary for B2B sourcing and shortage planning. This entry is written for hospital, clinic, and pharmacy procurement readers in the Neurology, Alzheimer's disease space. Availability may depend on jurisdiction and regulatory status; requests are quotation-based.
Donanemab (Kisunla): An anti-amyloid monoclonal antibody for early symptomatic Alzheimer's disease, administered as an intravenous infusion. Procurement-oriented reference for licensed buyers - not medical advice, and availability depends on region and authorization.
What this medication is commonly used for
Procurement teams reference Donanemab when aligning formulary decisions, documenting a named patient request, or preparing a quotation for a destination country where the product is not routinely stocked.
This section is informational only. Treatment decisions belong to qualified clinicians and local labeling.
Shortage and sourcing context
A recent approval with uneven jurisdictional coverage, so requests frequently concern regions where the product is not yet authorized. Expect questions about the destination country's regulatory route before any quotation is possible. Cold chain applies.
Who typically requests this medication
- Hospitals and hospital pharmacies managing formulary access
- Clinics and specialty clinics with defined treatment pathways
- Specialty pharmacies serving complex therapies
- Medical procurement teams coordinating licensed sourcing
Availability depends on market conditions and regulatory requirements. This page is informational and does not replace local governance.
Presentation and strength examples
- Dosage forms (examples): Concentrate for solution for infusion
- Strengths (examples): Presentation-dependent
- Active ingredient (INN): donanemab
Request availability for this medication
Submit a procurement inquiry for review against licensed wholesale networks. No guaranteed availability or shipment.
Request availabilityMore from the directory
Long-form reference: the sections above summarize procurement-oriented context. For extended narrative content where available, see also the structured description below.
Donanemab (Kisunla): An anti-amyloid monoclonal antibody for early symptomatic Alzheimer's disease, administered as an intravenous infusion. Procurement-oriented reference for licensed buyers - not medical advice, and availability depends on region and authorization.
Procurement context
Procurement teams reference Donanemab when aligning formulary decisions, documenting a named patient request, or preparing a quotation for a destination country where the product is not routinely stocked.
What makes it hard to source
A recent approval with uneven jurisdictional coverage, so requests frequently concern regions where the product is not yet authorized. Expect questions about the destination country's regulatory route before any quotation is possible. Cold chain applies.